FDA Gives Green Signal To Reviva Pharma's Late-Stage Schizophrenia Trial

Benzinga Real-time News ·  01/10/2022 20:16

The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia. The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia. Related: Reviva Pharma Stock Trading Higher On Detailed Positive Schizophrenia Study Results.Both Phase 3 trials will be initiated simultaneously by the end of January 2022.Price Action: RVPH shares are up 16.2% at $3.45 during the premarket session on the last check Monday.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write first comment